相关实验视频

Updated: May 14, 2025

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

在晚期分化甲状腺癌中对伦瓦提尼布的反应的预测因素:专注于CONUT得分

Edoardo Talpacci¹, Silvia Morelli¹, Vincenzo Leone¹

¹Section of Internal Medicine and Endocrine and Metabolic Sciences, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

|April 11, 2025

概括

伦瓦提尼布在晚期甲状腺癌中显示出有效性. 较低的营养状况 (CONUT评分) 和更好的表现状况 (ECOG) 预测放射性耐药差异化甲状腺癌患者的生存时间更长.

科学领域:

在瘤学瘤学.
临床药理学临床药理学

背景情况:

伦瓦提尼布已批准用于治疗渐进性放射性耐火的分化甲状腺癌 (RAI-R-DTC).
与SELECT研究相比,最初的经验表明结果可能会变化.
患者的特征可能会影响治疗反应.

研究的目的:

审查使用Lenvatinib治疗的晚期甲状腺癌患者的临床结果.
在单中心队列中识别生存预测因素.
评估营养状况 (CONUT分数) 和性能状况 (ECOG) 的预后值.

主要方法:

对22名以伦瓦丁尼布治疗的RAI-R-DTC进展的患者进行了回顾性分析.
评估基线临床特征,包括使用CONUT得分的营养状况.
评估整体生存期 (OS) 和无进展生存期 (PFS).

主要成果:

中位数OS为54个月,中位数PFS为21个月.
较低的基线CONUT得分与明显更长的PFS和OS相关.
较高的ECOG性能状态 (PS) 与增加的不良事件严重程度相关.
瘤反应是更好的PFS的重要预测因素.

结论:

伦瓦提尼布在渐进的高级RAI-R-DTC中显示出有效性.
最好的瘤反应,ECOG PS和CONUT得分是有价值的预后指标.
这些因素可以帮助为甲状腺癌患者个性化治疗策略.

关键词:

在 CONUT 得到的分数.伦瓦提尼布 (Lenvatinib) 是一种药物.没有进展的生存率.渐进性放射性耐火的分化甲状腺癌.

更多相关视频

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...